![Bone Targeting Agents in Patients with Prostate Cancer – APCCC](https://oncodaily.com/pub/uploads/2024/08/WhatsApp-Image-2024-08-21-at-01.02.19_fc480fb2.jpg)
Bone Targeting Agents in Patients with Prostate Cancer – APCCC
APCCC shared a post on LinkedIn:
“Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
Bone metastases are a common and critical complication of advanced Prostate Cancer , affecting around 90% of patients.
Effective management of bone involvement, particularly through the use of bone-targeting agents (BTAs) such as bisphosphonates and denosumab, is crucial for reducing skeletal-related events (SREs) and improving survival in metastatic cases.
However, these treatments carry risks, particularly osteonecrosis of the jaw (ONJ), a serious and debilitating side effect.
This review discusses the clinical benefits, common toxicities, and management strategies associated with BTAs in prostate cancer, with a focus on understanding and addressing ONJ.”
Authors: Veronica Mollica, Alessandro Rizzo, Matteo Rosellini, Andrea Marchetti, Angela Dalia Ricci, Alessia Cimadamore, Marina Scarpelli, Chiara Bonucci, Elisa Andrini, Costantino Errani, Matteo Santoni, Rodolfo Montironi, and Francesco Massari.
Source: APCCC/LinkedIn